Polymorphisms in OATP1B1 (OATP1B1*5 and OATP1B1*15) reduce transporter function, leading to higher systemic drug exposure, increased risk of statin-induced myopathy, and altered lipid metabolism, potentially worsening dyslipidemia [129]. Here, SLCO1B1 is linked to metabolic syndrome.